Last checked at 25 Sep 2014 11:03
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Synairgen Share News (SNG)
SNG Share
Price
SNG Share
News
SNG Share
Chat16
SNG Share
Trades18
SNG
Live RNS
SNG Share
Charts
SNG Level 2
Console
SNG Live
Share Price
SNG Broker
Ratings
SNG Directors
Deals
SNG Financial
Diary
SNG
Fundamentals
SNG Short
Positions
SNG
Media
Synairgen Information
Share Price Information for Synairgen (SNG)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
6.20
Bid:
5.52
Ask:
7.00
Change:
0.08 (1.31%)
Spread:
1.48 (26.812%)
Open:
6.20
High:
6.20
Low:
6.20
Prev. Close:
6.12
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Synairgen raises 2.5m pounds from placing
Wed, 18th Jul 2012 09:39
Synairgen, a Southampton-based research firm, has placed around 5.56m shares at 45p each, enabling the firm to progress with its primary programme following the successful clinical trial results of an asthma treatment product. The placing has raised £2.5m before expenses. In a related transaction, Lansdowne Partners and IP Group are subscribing for 1.1m and 1.01m placing shares respectively, giving them an interest in 15m and 13.7m, representing 20.00% and 18.24% of the company's enlarged issued share capital, respectively. The proceeds will be used to further develop its asthma treatment programme, which, following recent trials, has confirmed clinically important and statistically significant differences in favour of inhaled interferon beta as compared to placebo for patients with "difficult to treat" asthma (estimated to be 10% -20% in the adult asthma population) across a number of recognised asthma trial endpoints such as asthma symptoms, lung function, and exacerbations. As a result of the positive data, Synairgen believes that it is in a strong position to partner the programme to progress inhaled IFN-beta for multiple indications.As part of this process, and in order to ensure that Synairgen achieves the maximum value in any potential partnership deal, the company now intends to use the proceeds of the placing to bring forward a biomarker programme to support the development of inhaled IFN-beta and to further characterise the responder population. Funds will also be used to progress the company's drug development plan to maintain momentum on the programme and to be ready to commence the next planned studies with a partner in asthma and COPD in 2013.In addition, some of the funds will be used to initiate the firm's interaction with the US government in order to position it ahead of an exploration into the potential of inhaled IFN-beta as a broad spectrum antiviral for severe viral lung infections. Remaining funds will be used for working capital requirements. The shares will be admitted onto AIM on July 23rd. The share price fell 8.91% to 46p by 09:49.NR
More News
4 Jul 2014 12:11
Synairgen raises funds to develop AstraZeneca drug
Synairgen has placed 12.2m shares to raise funds for the assessment and preparation of SNG001, the drug recently licensed from AstraZeneca, across five projects that it has identified as the most suitable direction for its development. The drugs company raised around £5.3m before expenses after is
Read more4 Jul 2014 07:21
15 Jun 2014 12:28
Sunday share tips: Whitbread, Petra Diamonds, Empiric Student Property
Whitbread looks like a reliable investment despite the imminent departure of Chairman Anthony Habgood, Matthew Goodman said in the Sunday Times's Inside the City column. The company was a mess when Habgood took over in 2005 but he has sold peripheral businesses to focus on Premier Inn and Costa Coff
Read more12 Jun 2014 16:37
MARKET COMMENT: FTSE 100 Closes Slightly Higher Amid Iraqi Tensions
LONDON (Alliance News) - The FTSE 100 closed fractionally higher Thursday, having spent the day trading within a tight range, with oil and gas exploration and production company BG Group leading the gains as the price of oil climbed amid escalating violence in Iraq.
Read more
12 Jun 2014 10:23
TOP NEWS: Discount Retailer B&M Prices Biggest London IPO Of 2014
LONDON (Alliance News) - The following is a summary of top news stories Thursday.
----------
COMPANIES
----------
The initial public offering of B&M European Value Retail SA, the discount retailer chaired by former TescoRead more
12 Jun 2014 08:25
London open: Mining stocks pull FTSE 100 lower ahead of data
- Profit taking continues as miners fall - Traders await global economic data - Broker downgrades hit blue chips techMARK 2,839.63 -0.04% FTSE 100 6,827.09 -0.17% FTSE 250 16,073.58 -0.09% UK stocks opened flat on Thursday morning as weakness in the mining sector held back any chances of a rebound
Read more12 Jun 2014 07:42
AstraZeneca signs licence deal with Synairgen
British drugs maker AstraZeneca has signed a licence agreement with AIM-listed Synairgen for the development of SNG000l, a treatment for respiratory tract viral infections in patients with severe asthma. Under the deal, FTSE 100-listed Astra will pay Synairgen a $7.25m up-front fee and potential de
Read more12 Jun 2014 07:36
UK MORNING BRIEFING: AstraZeneca Signs Asthma Deal With Synairgen
LONDON (Alliance News) - UK shares have opened flat Thursday, following negative trading in the US and Asia overnight.
AstraZeneca is the third biggest gainer on the FTSE 100. The drugmaker said it has signed a global licence agreement with AIM-listed biotechnology
12 Jun 2014 06:52
AstraZeneca Licences Asthma Exacerbation Treatment From Synairgen
LONDON (Alliance News) - AstraZeneca PLC said Thursday that it had signed a global licence agreement with AIM-listed biotechnology company Synairgen PLC for its SNG001 compound for the treatment of infections that exacerbate asthma. The compound is used to treat respiratory tract infections
Read more20 Mar 2014 12:47
Synairgen Pretax Loss Narrows On Expenses
LONDON (Alliance News) - Synairgen PLC Thursday said its pretax loss narrowed in its full year 2013 as administrative expenses fell during the period. The respiratory drug discovery and development company said its pretax profit narrowed to GBP2.3 million from GBP2.5 million the previous ye
Read more5 Mar 2014 11:31
Synairgen Jumps As It Raises Cash While Progressing Licensing Talks
LONDON (Alliance News) - Synairgen PLC Wednesday said it has raised GBP1.5 million by placing 3.1 million shares at 48 pence each, money it will use for working capital while it progresses current licensing discussions through to a conclusion. In a statement, the respiratory drug discovery
Read more5 Mar 2014 08:31
UK MORNING BRIEFING: Standard Chartered Profits Fall, Cuts Bonus Pool
LONDON (Alliance News) - Shares have opened mostly lower Wednesday with small-caps out-performing large caps, following Tuesday's relief rally from lowered Ukraine tensions.
Standard Chartered has reported lower 2013 profit and a 15% reduction in its bonus pool, whi
5 Dec 2012 11:10
Synairgen reports 'significant progress'
Synairgen, a respiratory drug discovery and development company, has reported 'significant progress' since the end of June. The firm said that discussions with potential licensing partners for its SNG001 product have progressed, the company has engaged with the US government to investigate the pote
Read more